Science
Built to defeat
viral mutations
Virucidal Therapeutics Platform
A virucidal therapeutic platform based on validated rHDL production technology, designed to target enveloped viruses such as COVID-19, influenza, and mpox.
Virucidal rHDL(VH)
Virucidal rHDL—derived from virus + -cide (“to kill”)—is an rHDL conjugated with a viral receptor. VH induces intracellular viruses to self-destruct through their own mechanisms once they enter the cell.
Advantages
Resistance and mutation-resilient therapy
By exploiting the viral infection cycle, the virucidal mechanism carries a low risk of resistance.
Superior safety
Produced with human-derived components such as rHDL, making it highly safe for the body.
Virucidal platform technology
By modifying viral receptors, it can be designed to target a wide range of enveloped viruses.
MND-M8
In the viral receptor region of VH, sialic acid—known to recognize influenza viruses—was attached.
Compared to the natural infection mechanism, it prevents viral genetic material from entering the nucleus by exploiting the virus’s tendency to bind to sialic acid and induce membrane fusion. In addition, it does not exhibit cytotoxicity that randomly attacks other cells in the body, making it highly safe.
R&D Achievements
Discover the intellectual property activities we are pursuing around virucidal platform.